Nutrition, Metabolism & Cardiovascular Diseases
Volume 19, Issue 9 , Pages 634-640 , November 2009

Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study

  • G. de Simone

      Affiliations

    • Department of Clinical and Experimental Medicine, Federico II University of Naples, Italy
    • Division of Cardiology, Weill Cornell Medical College, New York, NY, USA
    • Corresponding Author InformationCorresponding author. Department of Clinical and Experimental Medicine, Federico II University of Naples, via S. Pansini n. 5, 80131 Naples, Italy. Tel.: +39 081 746 2013; fax: +39 081 546 6152.
    • ,
  • P.M. Okin

      Affiliations

    • Division of Cardiology, Weill Cornell Medical College, New York, NY, USA
    • ,
  • E. Gerdts

      Affiliations

    • Institute of Medicine, University of Bergen, and Haukeland University Hospital, Bergen, Norway
    • ,
  • M.H. Olsen

      Affiliations

    • Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
    • ,
  • K. Wachtell

      Affiliations

    • Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
    • ,
  • D.A. Hille

      Affiliations

    • Merck Research Laboratories, Blue Bell, PA, USA
    • ,
  • B. Dahlöf

      Affiliations

    • Sahlgrenska University Hospital, Östra, Göteborg, Sweden
    • ,
  • S.E. Kjeldsen

      Affiliations

    • Ullevål University Hospital, Oslo, Norway
    • ,
  • R.B. Devereux

      Affiliations

    • Division of Cardiology, Weill Cornell Medical College, New York, NY, USA

Received 15 October 2008 ,Revised 30 November 2008 ,Accepted 18 December 2008.

References 

  1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2716
  2. de Simone G, Olsen MH, Wachtell K, Hille DA, Dahlof B, Ibsen H, et al. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. J Hum Hypertens. 2007;21:625–632
  3. Chinali M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart study). Am J Cardiol. 2004;93:40–44
  4. Arcucci O, de Simone G, Izzo R, Rozza F, Chinali M, Rao MA, et al. Association of suboptimal blood pressure control with body size and metabolic abnormalities. J Hypertens. 2007;25:2296–2300
  5. Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in hypertension study. Circulation. 2006;113:1588–1596
  6. Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Hedner T, Ibsen H, et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study. Am J Hypertens. 1997;10:705–713
  7. Dahlof B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Hypertension. 1998;32:989–997
  8. de Simone G, Wachtell K, Palmieri V, Hille DA, Beevers G, Dahlof B, et al. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation. 2005;111:1924–1931
  9. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–2497
  10. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization Diabetes Res Clin Pract. 1999;44:21–26
  11. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281–303
  12. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study. Circulation. 2003;108:684–690
  13. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003
  14. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456–1462
  15. Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J, et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Blood Press. 2001;10:74–82
  16. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350–2356
  17. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–1083
  18. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux RB, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms J Am Soc Echocardiogr. 1989;2:358–367
  19. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458
  20. Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Lindholm LH, et al. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Hypertension. 2007;50:984–990
  21. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161–186
  22. Dunn RA, Pipberger HV, Holt JH, Barnard AC, Pipberger HA. Performance of conventional orthogonal and multiple-dipole electrocardiograms in estimating left ventricular muscle mass. Circulation. 1979;60:1350–1353
  23. Schillaci G, Pirro M, Pucci G, Mannarino MR, Gemelli F, Siepi D, et al. Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension. 2006;47:881–886
  24. Mule G, Cusimano P, Nardi E, Cottone S, Geraci C, Palermo A, et al. Relationships between metabolic syndrome and left ventricular mass in hypertensive patients: does sex matter?. J Hum Hypertens. 2008;22:788–795
  25. Escobar C, Barrios V, Calderon A, Barrios S, Echarri R, Navarro-Cid J, et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA study. J Clin Hypertens. 2008;10:208–214
  26. Mule G, Nardi E, Cottone S, Cusimano P, Volpe V, Piazza G, et al. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med. 2005;257:503–513
  27. de Simone G, Devereux RB, Chinali M, Best LG, Lee ET, Galloway JM, et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart study. Diabetes Care. 2007;30:1851–1856
  28. de Simone G, Devereux RB, Chinali M, Roman MJ, Lee ET, Resnick HE, et al. Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart study. Nutr Metab Cardiovasc Dis. 2008;[epub ahead of print]

PII: S0939-4753(09)00003-9

doi: 10.1016/j.numecd.2008.12.012

Nutrition, Metabolism & Cardiovascular Diseases
Volume 19, Issue 9 , Pages 634-640 , November 2009

Article Tools

* Image Usage & Resolution